Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Matthew S Davids, Yesid Alvarado Valero, Catherine Diefenbach, Daniel N. Egan, Shira N. Dinner, Monzr M. Al Malki, Kebede Begna, Avyakta Kallam, Sameem Abedin, Rachel Cook, Nathalie Javidi-Sharifi, Edward Dominguez, Lu Miao, Richard G Ghalie, Alexey Danilov

Blood (2023) 142 (Supplement 1): 4286.

https://doi.org/10.1182/blood-2023-179577

Published: 2023

Journal Articles

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

Jacob D. Soumerai, Catherine S. Diefenbach, Felipe Samaniego, Abhijeet Kumar, Michaela L. Tsai, Adam S. Asch, Deepa Jagadeesh, Vaishalee P. Kenkre, Izidore S. Lossos, Huda Salman, Farrukh T. Awan, Lu Miao, Richard G. Ghalie, Andrew D. Zelenetz

Blood (2022) 140 (Supplement 1): 189–191.

https://doi.org/10.1182/blood-2022-157563

Published: 2022

Journal Articles

A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML

Marina Konopleva, Danielle M. Brander, Krish Patel, Catherine S. Diefenbach, Yesid Alvarado, Olga Frankfurt, Monzr M. Al Malki, Alexey V. Danilov, Sameem Abedin, Kebede H. Begna, Avyakta Kallam, Richard G. Ghalie, Matthew S. Davids

Blood (2021) 138 (Supplement 1): 3423.

https://doi.org/10.1182/blood-2021-146079

Published: 2021

Journal Articles

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

Andrew D. Zelenetz, MD PhD, Jacob D. Soumerai, MD, Deepa Jagadeesh, MD MPH, Nishitha Reddy, MD, Anastasios Stathis, MD, Adam S. Asch, MD, Huda S. Salman, MD, Vaishalee P. Kenkre, MD, Haresh Jhangiani, MD MBA, Alexia Iasonos, PhD, Patel Krish, MD, Richard G Ghalie, MD MBA, John M. Pagel, MD PhD

Blood (2018) 132 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2018-99-115670

Published: 2018

Journal Articles

A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

Guillermo Garcia Manero, Ehab Atallah, MD, Samer K Khaled, MD, Martha Arellano, MD, Mrinal M Patnaik, MBBS, Olatoyosi Odenike, MD, Hamid Sayar, MD, Mohan Tummala, Prapti A. Patel, MD, Richard G. Ghalie, MD, Bruno C. Medeiros, MD

Blood (2016) 128 (22): 100.

https://doi.org/10.1182/blood.V128.22.100.100

Published: 2016

Journal Articles

Intra-Patient Variability in Fetal Hemoglobin Measurements over Time in Sickle Cell Disease Patients Not on Fetal Hemoglobin Inducing Agents

Esther E Knapp, MD MBE, Deepa Manwani, MD, Abdullah Kutlar, MD, Hillel W Cohen, DrPH, MPH, Richard G. Ghalie, MD

Blood (2014) 124 (21): 4096.

https://doi.org/10.1182/blood.V124.21.4096.4096

Published: 2014

Journal Articles

A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia

Poramin Patthamalai, Suthat Fuchareon, Nattawara Chaneiam, Richard G. Ghalie, David H. K. Chui, Michael S. Boosalis, Susan P. Perrine

Blood (2014) 123 (12): 1956–1957.

https://doi.org/10.1182/blood-2013-11-538470

Published: 2014

Journal Articles

A Phase 2 Trial Of The Fetal Hemoglobin Inducer HQK-1001 (2,2-dimethylbutyrate, Sodium Salt) In Non-Transfusion-Dependent β-Thalassemia

Adlette Inati, MD, Mario Kahale, MD, Susan P Perrine, MD, Ali T Taher, MD, Suzanne Koussa, MD, Hussein A Abbas, PhD, Therese Abi Nasr, MD, Richard G. Ghalie, MD

Blood (2013) 122 (21): 2261.

https://doi.org/10.1182/blood.V122.21.2261.2261

Published: 2013

Journal Articles

A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease

Abdullah Kutlar, MD, Marvin Reid, PhD, Ali T Taher, MD, Adlette Inati, MD, Miguel R. Abboud, MD, Amal El-Beshlawy, MD, George R. Buchanan, MD, Hedy Smith, MD PhD, Kenneth I. Ataga, MD, Nebu Koshy, MD, FACP, Lynne D Neumayr, MD, Punam Malik, M.D., Ofelia A. Alvarez, MD, Richard Ward, MBBS, MRCP, FRCPath, J Michael White, PhD, Elsa Johnson, MBA, Richard G. Ghalie, MD

Blood (2012) 120 (21): 998.

https://doi.org/10.1182/blood.V120.21.998.998

Published: 2012

Journal Articles

A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease

Abdullah Kutlar, MD, Adlette Inati, MD, Ali T Taher, MD, Amal El-Beshlawy, MD, Marvin Reid, PhD, Miguel R. Abboud, MD, Hedy Smith, MD, PhD, Kenneth I. Ataga, MD, George R. Buchanan, MD, Punam Malik, MD, Nebu Koshy, MD, Lynne Neumayr, MD, Maria Aiello, MA, Elsa Johnson, MBA, J Michael White, PhD, Richard G. Ghalie, MD

Blood (2011) 118 (21): 1066.

https://doi.org/10.1182/blood.V118.21.1066.1066

Published: 2011

Journal Articles

A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma

Arnold S. Freedman, MD, Sattva Neelapu, MD, Craig R Nichols, MD, Michael Robertson, MD, Benjamin Djulbegovic, MD, PhD, Jane N. Winter, MD, Daniel Gold, PhD, John Bender, PharmD, Morgan Stewart, PhD, Richard G. Ghalie, MD, MBA, Paul A. Hamlin, Jr., MD

Blood (2008) 112 (11): 236.

https://doi.org/10.1182/blood.V112.11.236.236

Published: 2008

Journal Articles

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

Omer N. Koc, MD, Charles Redfern, MD, Peter H. Wiernik, MD, Fred Rosenfelt, MD, Jane N. Winter, MD, Troy H. Guthrie, MD, Lawrence Kaplan, MD, Peter Holman, MD, John Densmore, MD, PhD, John Hainsworth, MD, Thomas S. Lin, MD, Rene A. Castillo, MD, Nalini Janakiraman, MD, Richard G. Ghalie, MD

Blood (2007) 110 (11): 3427.

https://doi.org/10.1182/blood.V110.11.3427.3427

Published: 2007

Journal Articles

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

Donald E. Tsai, MD, PhD, Selina Luger, MD, Allison Kemner, RN, Alison W. Loren, MD, Cezary Swider, PhD, Ami Goradia, MD, Charalambos Andreadis, MD, Richard G. Ghalie, MD, James Thompson, MD, David Porter, MD, Edward A. Stadtmauer, MD, Stephen J. Schuster, MD, Alexander Perl, MD, Adam Bagg, MD, Steven Goldstein, MD, Martin Carroll, MD

Blood (2006) 108 (11): 1955.

https://doi.org/10.1182/blood.V108.11.1955.1955

Published: 2006

Journal Articles

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

Andres Forero, Paul L. Weiden, Julie M. Vose, Susan J. Knox, Albert F. LoBuglio, Jordan Hankins, Michael L. Goris, Vincent J. Picozzi, Don B. Axworthy, Hazel B. Breitz, Robert B. Sims, Richard G. Ghalie, Sui Shen, Ruby F. Meredith

Blood (2004) 104 (1): 227–236.

https://doi.org/10.1182/blood-2003-09-3284

Published: 2004

NARROW

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Safety and Efficacy of the PI3Kδ Inhibitor Zandelisib in Combination with the BTK Inhibitor Zanubrutinib in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Mantle Cell Lymphoma (MCL)

A Phase 1 Dose-Escalation Study of the Oral CDK Inhibitor Voruciclib in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia (AML): Preliminary Results of the Completed Dose Escalation Stage in AML

Preliminary Safety and Efficacy Results with an Intermittent Schedule of the PI3kδ Inhibitor ME-401 Alone or in Combination with Rituximab for B-Cell Malignancies

A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit

Intra-Patient Variability in Fetal Hemoglobin Measurements over Time in Sickle Cell Disease Patients Not on Fetal Hemoglobin Inducing Agents

A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia

A Phase 2 Trial Of The Fetal Hemoglobin Inducer HQK-1001 (2,2-dimethylbutyrate, Sodium Salt) In Non-Transfusion-Dependent β-Thalassemia

A Randomized, Open-Label, Multicenter, Dose Escalation Study of HQK-1001 (2,2-Dimethylbutyrate, Sodium Salt) in Sickle Cell Disease

A Phase 2 Clinical Study of HQK-1001 (2,2-dimethylbutyrate, sodium salt), a Fetal Hemoglobin Inducer, in Patients with Sickle Cell Disease

A Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy with Mitumprotimut-T (ID-KLH) and GM-CSF Following Rituximab in Patients with CD20+ Follicular Lymphoma

Continued Late Conversion to Complete Remission (CR/CRu) and Durability of Remission (DUR) in Pts with B-Cell Follicular Lymphoma (FL) Treated with Rituximab Followed by Mitumprotimut-T (Id-KLH, FavId®) Active Immunotherapy.

A Phase I Trial of Bexarotene, a Retinoid X Receptor Agonist, in non-M3 Acute Myeloid Leukemia: Evidence of Myeloid Differentiation and Clinical Activity.

Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only